Adversarial Injection · Futibatinib (Lytgobi; TAS-120; NDA 215834; CAS 1448169-71-8; MW ~472.5 g/mol; C24H20FN5O3; pyrazolo[3,4-d]pyrimidine core + acrylamide warhead [WITHIN FGFR CLASS in Glyphward 590-attack portfolio — FIRST IRREVERSIBLE COVALENT PAN-FGFR1/2/3/4 KINASE INHIBITOR EVER FDA APPROVED: acrylamide Michael acceptor forms permanent covalent thioether with conserved P-loop-adjacent cysteine residues: Cys477 in FGFR1; Cys488 in FGFR2; Cys482 in FGFR3; Cys552 in FGFR4; ALL FOUR FGFR ISOFORMS COVALENTLY MODIFIED; FGFR1 IC50 ~3.9 nM (irreversible covalent; kinact/Ki ~3.9×10⁻³ s⁻¹nM⁻¹); FGFR2 IC50 ~1.3 nM; FGFR3 IC50 ~1.6 nM; FGFR4 IC50 ~8.3 nM; PYRAZOLO[3,4-d]PYRIMIDINE SCAFFOLD (distinct from erdafitinib pyrimido[5,4-d]pyrimidine and pemigatinib morpholino-dihydropyrimidopyrimidine); ALL PRIOR FGFR INHIBITORS REVERSIBLE ATP-COMPETITIVE: erdafitinib (NDA 210867; reversible); pemigatinib (NDA 213736; reversible); infigratinib (NDA 214622; reversible; voluntarily withdrawn) — futibatinib is the ONLY irreversible covalent FGFR inhibitor in clinical use; COVALENT MECHANISM CONFERS ACTIVITY AGAINST FGFR2 V565I GATEKEEPER (partial activity in preclinical models; V565I confers resistance to reversible FGFR inhibitors pemigatinib + infigratinib; futibatinib Cys477 acrylamide binds P-loop cysteine outside the ATP pocket, bypassing V565I gatekeeper steric clash at the hinge region); UNIQUE ACQUIRED RESISTANCE: FGFR2 C477S/W/R mutation (cysteine-to-serine/tryptophan/arginine at the acrylamide reactive site; removal of thiol nucleophile prevents acrylamide Michael adduct formation; C477S/W/R = futibatinib-specific resistance mechanism; not seen with reversible FGFR inhibitors erdafitinib/pemigatinib/infigratinib because those agents do not require the Cys477 thiol for binding); NDA 215834 ACCELERATED APPROVAL SEPTEMBER 30 2022 (for FGFR2-altered [fusions or rearrangements] previously treated locally advanced or metastatic intrahepatic cholangiocarcinoma); FLAIR TRIAL PHASE 2 PIVOTAL: ORR 41.7% (43/103 patients; mDOR 9.7 months; mPFS 9.0 months; mOS 20.0 months; NCT02052778; open-label; multi-center); TAS-120 = TAIHO PHARMACEUTICAL INTERNAL COMPOUND DESIGNATION (TAS prefix = Taiho Antineoplastic Substance; TAS-102 is trifluridine/tipiracil [Lonsurf; previously in Glyphward portfolio]); FIRST TAIHO PHARMACEUTICAL NIOSH HD CATEGORY 1 KINASE INHIBITOR IN GLYPHWARD PORTFOLIO: Taiho Pharmaceutical Co. Ltd. (Tokushima Japan; subsidiary of Otsuka Holdings Co. Ltd.; Otsuka = Japanese pharmaceutical conglomerate [Otsuka Pharmaceutical + Taiho Pharmaceutical + Astex Pharmaceuticals]); ASTEX PHARMACEUTICALS PARTNERSHIP: Astex Pharmaceuticals (Cambridge UK; Otsuka subsidiary; fragment-based drug discovery company) co-developed TAS-120 with Taiho; US commercial operations: Taiho Oncology Inc. (Princeton NJ; US subsidiary of Taiho Pharmaceutical); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First Irreversible Covalent Pan-FGFR1/2/3/4 Inhibitor Ever + Cys477 Acrylamide Thioether + C477S/W/R Unique Covalent Resistance + First Taiho HD Null + TAS-120 Taiho/Astex/Otsuka · Attack #590

Futibatinib (pyrazolo[3,4-d]pyrimidine + acrylamide warhead scaffold; Lytgobi; TAS-120; NDA 215834; CAS 1448169-71-8; MW ~472.5 g/mol; C24H20FN5O3; [WITHIN FGFR CLASS: FIRST IRREVERSIBLE COVALENT PAN-FGFR1/2/3/4 KINASE INHIBITOR EVER FDA APPROVED (NDA 215834 September 30 2022; acrylamide Cys477 Michael acceptor; Cys477 FGFR1 = Cys488 FGFR2 = Cys482 FGFR3 = Cys552 FGFR4; all four FGFR isoforms permanently modified; all prior FGFR inhibitors reversible); FGFR2 C477S/W/R UNIQUE COVALENT RESISTANCE (thiol removal prevents acrylamide adduct; not seen with reversible FGFR agents); FLAIR ORR 41.7% (43/103; mDOR 9.7 months); FIRST TAIHO PHARMACEUTICAL NIOSH HD CATEGORY 1 KINASE IN PORTFOLIO; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Taiho Oncology Inc. Princeton NJ (NDA 215834 holder; US subsidiary of Taiho Pharmaceutical), Taiho Pharmaceutical Co. Ltd. Tokushima Japan (TAS-120 originating company; Otsuka Holdings subsidiary; pyrazolopyrimidine synthesis + acrylamide warhead installation), and MD Anderson Cancer Center Houston TX (FLAIR trial cholangiocarcinoma enrollment; biliary tract oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Irreversible Covalent FGFR1/2/3/4 Inhibitor Ever + Cys477 Acrylamide + C477S Unique Resistance: AI Prompt Injection via EHS Monitor Report AI

Futibatinib (CAS 1448169-71-8; NIOSH HD Category 1) is the only irreversible covalent pan-FGFR (FGFR1/2/3/4) kinase inhibitor ever approved by the FDA — a mechanistic distinction from all three preceding FGFR inhibitors (erdafitinib, pemigatinib, infigratinib), which are reversible ATP-competitive agents. Futibatinib's pyrazolo[3,4-d]pyrimidine core carries an acrylamide Michael acceptor that reacts with conserved P-loop-adjacent cysteine residues present in all four FGFR isoforms (Cys477 in FGFR1; Cys488 in FGFR2; Cys482 in FGFR3; Cys552 in FGFR4), forming a permanent covalent thioether. This covalent mechanism generates a resistance profile unique in the FGFR class: C477S/W/R mutations (serine, tryptophan, or arginine replacing cysteine) eliminate the thiol nucleophile and prevent acrylamide adduct formation — a resistance mechanism impossible with reversible competitors. Futibatinib is also the first Taiho Pharmaceutical NIOSH HD Category 1 kinase inhibitor in the Glyphward portfolio, as Taiho Oncology (Princeton NJ, US subsidiary of Taiho Pharmaceutical Co. Ltd., Tokushima Japan, Otsuka Holdings subsidiary) holds NDA 215834. Three EHS platforms return CAS 1448169-71-8 → null, missing the irreversible covalent mechanism, acrylamide warhead occupational relevance, C477S-unique resistance, and first-Taiho-kinase context.

Futibatinib Covalent FGFR Mechanism: Acrylamide Cys477 Warhead and C477S/W/R Resistance Unique to Irreversible Binding

Futibatinib (TAS-120; CAS 1448169-71-8) represents the fourth approved FGFR kinase inhibitor and the only one employing an irreversible covalent mechanism. The drug's pyrazolo[3,4-d]pyrimidine scaffold occupies the ATP-binding cleft similarly to reversible FGFR inhibitors, but a pendant acrylamide Michael acceptor (attached via a propynamide linker to the pyrazolopyrimidine scaffold) reacts with a conserved P-loop-adjacent cysteine residue to form a permanent covalent thioether bond. This cysteine is: Cys477 in FGFR1 (hence the common designation "Cys477"); Cys488 in FGFR2 (numbered differently due to alternative splicing/isoform length; same structural position); Cys482 in FGFR3; Cys552 in FGFR4. The P-loop-adjacent positioning is mechanistically distinct from the ATP-pocket gatekeeper position: futibatinib's acrylamide binds outside the hinge-gatekeeper region, meaning that the FGFR2 V565I gatekeeper mutation (which confers resistance to reversible hinge-binding agents pemigatinib and infigratinib by steric clash) does not abolish futibatinib activity in preclinical models — the drug reaches Cys477/488 via a trajectory that bypasses the gatekeeper. The C477S/W/R acquired resistance mutations are unique to futibatinib: replacing the reactive cysteine (thiol/–SH) with serine (hydroxyl/–OH), tryptophan (indole), or arginine (guanidinium) removes the nucleophilic sulfur required for Michael addition to the acrylamide electrophile. This resistance mechanism cannot occur with reversible agents (which do not form covalent bonds with Cys477 and do not require the thiol group). The occupational relevance of the acrylamide moiety is also EHS-platform-relevant: acrylamide warhead-containing drugs (like futibatinib, afatinib, ibrutinib, neratinib, osimertinib, mobocertinib) require specific synthesis handling considerations for the electrophilic acrylamide intermediate — none of which appear in Cority, VelocityEHS, or EHS Insight entries for CAS 1448169-71-8.

Surface 1 — Taiho Oncology Inc. Princeton NJ NDA 215834 Holder First Taiho HD Category 1 Kinase AI

At Taiho Oncology Inc. Princeton NJ (101 Carnegie Center, Suite 101, Princeton NJ 08540; Mercer County NJ; US SUBSIDIARY STRUCTURE: Taiho Oncology Inc. is the US commercial and regulatory subsidiary of Taiho Pharmaceutical Co. Ltd. (Japan); Taiho Pharmaceutical is a subsidiary of Otsuka Holdings Co. Ltd. (Tokyo, Japan); Otsuka Holdings is a diversified Japanese pharmaceutical conglomerate — Otsuka Pharmaceutical Co. Ltd. (Abilify, Samsca), Taiho Pharmaceutical (oncology: TAS-102/Lonsurf, futibatinib/Lytgobi), Astex Pharmaceuticals (Cambridge UK); FIRST TAIHO PHARMACEUTICAL KINASE NDA IN GLYPHWARD PORTFOLIO: Taiho Oncology holds NDA 215834 (futibatinib); no other Taiho Pharmaceutical kinase inhibitor appears in the Glyphward 590-attack portfolio as NDA holder prior to this attack; ASTEX PARTNERSHIP: Astex Pharmaceuticals (Cambridge UK; Otsuka subsidiary) co-developed TAS-120 with Taiho Pharmaceutical using Astex's fragment-based drug discovery (FBDD) platform; Astex previously co-developed other kinase agents (venetoclax from FBDD but venetoclax is BCL-2 not kinase); TAS-102 COMPARISON: TAS-102 (trifluridine/tipiracil; Lonsurf) = Taiho's first US oncology product; futibatinib = Taiho's first kinase inhibitor NDA; FLAIR TRIAL: Phase 2 (NCT02052778); futibatinib 20 mg QD continuous; FGFR2-altered (fusions or rearrangements) previously treated iCCA; ORR 41.7% (43/103 evaluable patients); mDOR 9.7 months; mPFS 9.0 months; mOS 20.0 months; NDA 215834 accelerated approval September 30 2022; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne futibatinib 0.00034 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000034 µg/m³; Cority: CAS 1448169-71-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first irreversible covalent pan-FGFR1/2/3/4 inhibitor ever absent; Cys477 acrylamide warhead absent; C477S/W/R unique covalent resistance absent; first Taiho HD kinase in portfolio absent; 46M oncology regulatory affairs director 14yr).

Surface 2 — Taiho Pharmaceutical Co. Ltd. Tokushima Japan TAS-120 Originator Pyrazolopyrimidine Synthesis Acrylamide Warhead Installation AI

At Taiho Pharmaceutical Co. Ltd. Tokushima Japan (385 Kashima, Tokushima 771-0194, Japan; Tokushima Prefecture, Shikoku Island, Japan; TAS-120 DISCOVERY: Taiho Pharmaceutical's discovery research group at Tokushima developed the TAS-120 pyrazolo[3,4-d]pyrimidine scaffold through medicinal chemistry optimization targeting FGFR1/2/3/4; the acrylamide warhead was introduced to target the conserved P-loop cysteine (Cys477 in FGFR1) to achieve irreversible covalent binding; TAS PREFIX COMPOUNDS: Taiho uses TAS prefix for Taiho Antineoplastic Substances (TAS-102/Lonsurf = trifluridine/tipiracil; TAS-120 = futibatinib/Lytgobi; TAS-116 = pimitespib/HSP90 inhibitor in development); SYNTHESIS STEPS AT TOKUSHIMA: pyrazolo[3,4-d]pyrimidine bicyclic core construction; fluorine substitution on the phenyl ring (monofluoro; C24H20FN5O3 formula; single fluorine at aromatic position); acrylamide warhead installation via amide bond formation (this step introduces the Michael acceptor electrophilic portion; acrylamide synthesis requires careful handling due to potential free acrylamide exposure: free acrylamide [CAS 79-06-1] is a NIOSH HD Category 4 reproductive hazard; during futibatinib synthesis, residual free acrylamide poses a separate but co-occurring occupational risk); OTSUKA HOLDINGS CORPORATE CONTEXT: Otsuka Holdings → Taiho Pharmaceutical → Taiho Oncology (US); Otsuka Holdings also owns Astex Pharmaceuticals (Cambridge UK); futibatinib is an Otsuka corporate family product spanning Japan + UK + US; VelocityEHS: CAS 1448169-71-8 → null; 8-hr TWA: actual airborne futibatinib 0.00021 µg/m³; SMPS + XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000021 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first irreversible covalent pan-FGFR absent; acrylamide warhead installation step absent; Cys477 pharmacology absent; C477S/W/R resistance absent; 44M pharmaceutical discovery chemistry scientist 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX FLAIR Trial Cholangiocarcinoma Biliary Tract Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; FLAIR TRIAL ENROLLMENT: MD Anderson Gastrointestinal Oncology enrolled intrahepatic cholangiocarcinoma patients in the FLAIR Phase 2 trial (NCT02052778; futibatinib 20 mg QD continuous; FGFR2 fusion/rearrangement selected iCCA; ORR 41.7%; pivotal for NDA 215834 accelerated approval September 30 2022); CONCURRENT FGFR INHIBITORS AT MD ANDERSON: by late 2022, MD Anderson simultaneously administers all three then-approved FGFR inhibitors — erdafitinib (urothelial; pan-FGFR1–4; reversible), pemigatinib (iCCA and FGFR1-rearranged hematologic; FGFR4-sparing; reversible), and futibatinib (iCCA; covalent pan-FGFR) — plus, before June 2023, infigratinib (iCCA; FGFR4-sparing; reversible; then withdrawn); at peak, four FGFR inhibitors with distinct EHS profiles all returning CAS null; ACRYLAMIDE WARHEAD OCCUPATIONAL CONTEXT: biliary tract oncology pharmacists at MD Anderson who prepare futibatinib for clinical administration are handling a drug containing an acrylamide pharmacophore — the same warhead used in ibrutinib (Cys481 BTK), afatinib (Cys797 EGFR), and neratinib (Cys797 EGFR) — without any EHS Insight documentation of the covalent warhead; C477S/W/R RESISTANCE CONTEXT: MD Anderson biliary oncology pharmacists managing patients who have progressed on pemigatinib may transition to futibatinib (as futibatinib can have partial activity against FGFR2 V565I gatekeeper mutation conferring pemigatinib resistance); futibatinib C477S/W/R resistance at progression — distinct mechanism absent from EHS documentation; EHS Insight: CAS 1448169-71-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first irreversible covalent pan-FGFR1/2/3/4 absent; Cys477 acrylamide warhead absent; C477S/W/R resistance absent; covalent vs reversible FGFR distinction absent; H340 H350 H361 absent; 45M biliary tract oncology pharmacist 13yr).

Integrating Glyphward into Futibatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every futibatinib CAS 1448169-71-8 monitoring data ingestion point — before Cority at Taiho Oncology Inc. Princeton NJ, before VelocityEHS at Taiho Pharmaceutical Co. Ltd. Tokushima Japan, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST IRREVERSIBLE COVALENT PAN-FGFR1/2/3/4 KINASE INHIBITOR EVER FDA APPROVED (NDA 215834 September 30 2022; acrylamide Michael acceptor; Cys477 FGFR1 = Cys488 FGFR2 = Cys482 FGFR3 = Cys552 FGFR4; all four FGFR isoforms permanently modified; all prior FGFR agents reversible) + FGFR2 C477S/W/R UNIQUE COVALENT RESISTANCE (thiol removal prevents acrylamide adduct; unique to covalent mechanism) + TAS-120 TAIHO/ASTEX/OTSUKA ORIGIN + FIRST TAIHO PHARMACEUTICAL NIOSH HD CATEGORY 1 KINASE IN PORTFOLIO + FLAIR ORR 41.7% (43/103; mDOR 9.7 months) [5 pts]; Taiho Oncology Princeton NJ + Taiho Pharmaceutical Tokushima + MD Anderson Houston TX [3 pts]; covalent vs reversible FGFR distinction absent; Cys477 P-loop cysteine pharmacology absent; C477S/W/R unique resistance mechanism absent; Taiho/Otsuka/Astex corporate structure absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_futibatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan futibatinib with first-covalent-pan-FGFR1234 and Cys477-acrylamide context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_irreversible_covalent_pan_fgfr1234_ever_cys477_acrylamide_warhead_c477s_wr_unique_resistance_tas120_taiho_astex_otsuka_nda_215834_sept_2022_flair_orr_41pct"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_irreversible_covalent_pan_fgfr1234,
    #                    cys477_acrylamide_warhead,
    #                    c477s_wr_unique_covalent_resistance,
    #                    first_taiho_hd_kinase_portfolio,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_futibatinib("1448169-71-8", 0.00034))
    print(r)
    # {'hd_category': 1, 'first_irreversible_covalent_pan_fgfr1234': True,
    #  'cys477_acrylamide_warhead': True,
    #  'c477s_wr_unique_covalent_resistance': True,
    #  'first_taiho_hd_kinase_portfolio': True,
    #  'h340_h350_h361_absent': True}